Oncobiologics (NASDAQ:OTLK) Receives Sell (D-) Rating from Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Oncobiologics (NASDAQ:OTLK) in a research note published on Friday,Weiss Ratings reports.

Several other research analysts have also commented on OTLK. Zacks Research lowered Oncobiologics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 27th. Chardan Capital reiterated a “neutral” rating and issued a $3.00 target price on shares of Oncobiologics in a research report on Thursday, August 28th. Guggenheim downgraded Oncobiologics from a “buy” rating to a “neutral” rating in a research note on Thursday, August 28th. HC Wainwright restated a “neutral” rating on shares of Oncobiologics in a research note on Tuesday, September 30th. Finally, Ascendiant Capital Markets lowered their price objective on Oncobiologics from $21.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, September 22nd. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.00.

Oncobiologics Trading Up 1.6%

Shares of OTLK opened at $1.26 on Friday. The firm has a market cap of $55.97 million, a price-to-earnings ratio of -2.21 and a beta of 0.56. The stock has a 50 day moving average of $1.22 and a 200-day moving average of $1.62. Oncobiologics has a 52 week low of $0.79 and a 52 week high of $6.98.

Oncobiologics (NASDAQ:OTLK) last issued its earnings results on Thursday, August 14th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.02). The firm had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.66 million. On average, sell-side analysts predict that Oncobiologics will post -2.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in shares of Oncobiologics by 74.1% in the first quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock worth $126,000 after purchasing an additional 44,063 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Oncobiologics by 42.7% in the first quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock worth $103,000 after purchasing an additional 25,351 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Oncobiologics by 865.2% in the second quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock worth $39,000 after purchasing an additional 21,941 shares in the last quarter. Institutional investors own 11.20% of the company’s stock.

About Oncobiologics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.